Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) plus trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Planchard, David
Besse, Benjamin
Groen, Harry
Hashemi, Sayed
Mazieres, Julien
Kim, Tae Min
Quoix, Elisabeth A.
Souquet, Pierre Jean
Barlesi, Fabrice
Baik, Christina S.
Villaruz, Liza C.
Kelly, Ronan Joseph
Zhang, Shirong
Tan, Monique
Gasal, Eduard
Santarpia, Libero
Johnson, Bruce E.
机构：
[1] Inst Gustave Roussy, Thorac Team, Villejuif, France
[2] Univ Paris Sud, Gustave Roussy, Villejuif, France
[3] Univ Groningen, Groningen, Netherlands
[4] Univ Med Ctr Groningen, Groningen, Netherlands
[5] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[6] CHU Toulouse, Hop Larrey, Toulouse, France
[7] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[8] Univ Hosp Strasbourg, Strasbourg, France
[9] Hop Jour, Pierre Benitef, France
[10] Aix Marseille Univ, AP HM, Marseille, France
[11] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[12] Univ Pittsburgh, Med Ctr, Hillman Canc Ctr, Pittsburgh, PA USA
[13] Baylor Univ, Med Ctr, Dallas, TX USA
[14] Novartis Pharmaceut, E Hanover, NJ USA
[15] Novartis Pharma AG, Basel, Switzerland
[16] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9593
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).
    Planchard, David
    Groen, Harry J. M.
    Kim, Tae Min
    Rigas, James R.
    Souquet, Pierre Jean
    Baik, Christina S.
    Barlesi, Fabrice
    Mazieres, Julien
    Quoix, Elisabeth A.
    Curtis, C. Martin
    Mookerjee, Bijoyesh
    Bartlett-Pandite, Arundathy N.
    Tucker, Christine
    D'Amelio, Anthony
    Johnson, Bruce E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Updated survival of patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D plus trametinib (T) in the phase II BRF113928 study.
    Planchard, David
    Besse, Benjamin
    Kim, Tae Min
    Quoix, Elisabeth A.
    Souquet, Pierre jean
    Mazieres, Julien
    Barlesi, Fabrice
    Groen, Harry J. M.
    Smit, Egbert F.
    Baik, Christina S.
    Cho, Byoung Chul
    Kelly, Ronan Joseph
    Socinski, Mark A.
    Novello, Silvia
    Rigas, James R.
    Giannone, Vanessa
    D'amelio, Anthony Michael
    Zhang, Pingkuan
    Mookerjee, Bijoyesh
    Johnson, Bruce E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC)
    Planchard, D.
    Smit, E. F.
    Groen, H. J. M.
    Mazieres, J.
    Besse, B.
    Helland, A.
    Giannone, V.
    D'Amelio, A.
    Zhang, P.
    Mookerjee, B.
    Johnson, B.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report
    Janet Pan
    Clinical Drug Investigation, 2019, 39 : 1003 - 1007
  • [5] Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report
    Pan, Janet
    CLINICAL DRUG INVESTIGATION, 2019, 39 (10) : 1003 - 1007
  • [6] Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib
    Chalmers, Anna
    Cannon, Laura
    Akerley, Wallace
    ONCOLOGIST, 2019, 24 (07): : 963 - 972
  • [7] Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
    Subbiah, V
    Kreitman, R. J.
    Wainberg, Z. A.
    Cho, J. Y.
    Schellens, J. H. M.
    Soria, J. C.
    Wen, P. Y.
    Zielinski, C. C.
    Cabanillas, M. E.
    Boran, A.
    Ilankumaran, P.
    Burgess, P.
    Salas, T. Romero
    Keam, B.
    ANNALS OF ONCOLOGY, 2022, 33 (04) : 406 - 415
  • [8] An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC; BRF113928).
    Planchard, David
    Besse, Benjamin
    Groen, Harry J. M.
    Souquet, Pierre Jean
    Quoi, Elisabeth A.
    Baik, Christina S.
    Barlesi, Fabrice
    Kim, Tae Min
    Mazieres, Julien
    Novello, Silvia
    Rigas, James R.
    Upalawanna, Allison
    D'amelio, Anthony Michael
    Zhang, Pingkuan
    Mookerjee, Bijoyesh
    Johnson, Bruce E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] MANAGEMENT OF ADVERSE EVENTS IN PATIENTS WITH BRAF V600E-MUTANT NON-SMALL CELL LUNG CANCER TREATED WITH COMBINATION DABRAFENIB PLUS TRAMETINIB
    Wallace, Deborah
    Skotte, Emily
    Johnson, Douglas
    Horn, Leora
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [10] Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
    Long, G. V.
    Flaherty, K. T.
    Stroyakovskiy, D.
    Gogas, H.
    Levchenko, E.
    de Braud, F.
    Larkin, J.
    Garbe, C.
    Jouary, T.
    Hauschild, A.
    Chiarion-Sileni, V.
    Lebbe, C.
    Mandala, M.
    Millward, M.
    Arance, A.
    Bondarenko, I.
    Haanen, J. B. A. G.
    Hansson, J.
    Utikal, J.
    Ferraresi, V.
    Mohr, P.
    Probachai, V.
    Schadendorf, D.
    Nathan, P.
    Robert, C.
    Ribas, A.
    Davies, M. A.
    Lane, S. R.
    Legos, J. J.
    Mookerjee, B.
    Grob, J. -J.
    ANNALS OF ONCOLOGY, 2017, 28 (07) : 1631 - 1639
12345